Management of Chronic Vulvitis
Chronic vulvitis requires identification of the underlying etiology before treatment, as the term encompasses multiple distinct conditions with different management strategies—most commonly vulvovaginal candidiasis, vulvar psoriasis, and lichen sclerosus.
Diagnostic Approach
The first critical step is determining whether this represents infectious or inflammatory disease, as chronic vulvitis is a descriptive term rather than a specific diagnosis 1, 2.
Key Clinical Features to Assess:
- Presence or absence of vaginal involvement: Vulvitis without vaginitis suggests inflammatory dermatoses (psoriasis, lichen sclerosus) rather than candidiasis 1, 2
- Vaginal pH: Normal pH (≤4.5) supports candidiasis; elevated pH suggests bacterial vaginosis or other causes 3, 4
- Microscopy and culture: Wet mount with 10% KOH to visualize yeast/pseudohyphae; culture remains gold standard for fungal diagnosis 4, 5
- Extragenital skin examination: 65-71% of patients with vulvar psoriasis have psoriasis elsewhere 6, 2
Common pitfall: Pre-pubertal girls are frequently misdiagnosed with chronic candidiasis when they actually have psoriasis or atopic dermatitis—candidiasis is essentially absent in Tanner Stage 1 girls 1.
Management Based on Etiology
If Vulvovaginal Candidiasis (VVC) is Confirmed:
Uncomplicated VVC:
- Topical azole therapy (clotrimazole 1% cream 5g intravaginally for 7-14 days, miconazole 2% cream 5g for 7 days, or terconazole 0.4% cream for 7 days) 4
- Alternative: Fluconazole 150 mg oral single dose 4, 7
- Efficacy: 80-90% symptom relief and negative cultures 3, 4
Recurrent VVC (≥4 episodes/year):
- Induction phase: 10-14 days of topical azole or oral fluconazole 7
- Maintenance phase: Fluconazole 150 mg weekly for 6 months 4, 7
- Obtain vaginal cultures to identify non-albicans species (present in 10-20% of recurrent cases) 4
Non-albicans VVC (particularly C. glabrata):
- First-line: Boric acid 600 mg intravaginal gelatin capsule daily for 14 days 7
- Alternatives: Nystatin 100,000-unit suppositories daily for 14 days, or 17% flucytosine cream with 3% amphotericin B cream for 14 days 7
Important caveat: Partner treatment is not routinely recommended as VVC is not sexually transmitted, except in women with recurrent infection where it may be considered 4.
If Inflammatory Dermatosis (Non-Infectious):
Vulvar Psoriasis:
This presents as chronic erythematous vulvitis without vaginitis, often bilaterally symmetrical, well-demarcated, with or without scale 2.
- Induction treatment: Potent topical corticosteroid ointment (e.g., clobetasol propionate 0.05%) 6, 2
- Maintenance treatment: Moderate-potency topical corticosteroid with topical tar solution or calcipotriol 6, 2
- Duration: Long-term management required as this is a chronic relapsing condition 2
- Success rate: 93.8% disease suppression with this approach 2
Critical point: Perianal involvement occurs in 48-50% of vulvar psoriasis cases 6, 2.
Plasma Cell Vulvitis (Zoon's Vulvitis):
- Characterized by well-demarcated shiny erythematous patches on genital mucosa 8
- Treatment: Topical corticosteroids initially; lasers or surgical management may be needed for long-term remission 8
- Diagnosis often requires biopsy showing plasma cell infiltrate and siderophages 8
Special Populations:
Pregnancy:
- Only topical azole therapy should be used (clotrimazole, miconazole, butoconazole, terconazole) 3
- Recommend 7-day regimens during pregnancy 3
- Avoid oral fluconazole: Associated with spontaneous abortion and congenital defects 5
HIV-Infected Women:
- Treat with same regimens as HIV-negative women 3
- Lower CD4+ counts associated with increased VVC rates 5
When Initial Treatment Fails:
- Re-culture to identify non-albicans species or confirm diagnosis 4
- Consider inflammatory dermatoses if cultures negative and no response to antifungals 1, 2
- Evaluate for contact dermatitis from topical antifungal overuse 1
- Consider biopsy if diagnosis uncertain or treatment-resistant 2, 8
Major pitfall: Prolonged empiric antifungal treatment without confirmed candidiasis can delay diagnosis of inflammatory conditions and worsen symptoms through contact irritation 1.